Literature DB >> 27890361

Iron dysregulation in beta-thalassemia.

Kamonlak Leecharoenkiat1, Pathrapol Lithanatudom2, Wannapa Sornjai3, Duncan R Smith4.   

Abstract

Iron deficiency anemia and iron overload conditions affect more than one billion people worldwide. Iron homeostasis involves the regulation of cells that export iron into the plasma and cells that utilize or store iron. The cellular iron balance in humans is primarily mediated by the hepcidin-ferroportin axis. Ferroportin is the sole cellular iron export protein, and its expression is regulated transcriptionally, post-transcriptionally and post-translationally. Hepcidin, a hormone produced by liver cells, post-translationally regulates ferroportin expression on iron exporting cells by binding with ferroportin and promoting its internalization by endocytosis and subsequent degradation by lysosomes. Dysregulation of iron homeostasis leading to iron deposition in vital organs is the main cause of death in beta-thalassemia patients. Beta-thalassemia patients show marked hepcidin suppression, ineffective erythropoiesis, anemia and iron overload. Beta-thalassemia is common in the Mediterranean region, Southeast Asia and the Indian subcontinent, and the focus of this review is to provide an update on the factors mediating hepcidin related iron dysregulation in beta-thalassemia disease. Understanding this process may pave the way for new treatments to ameliorate iron overloading and improve the long term prognosis of these patients. Copyright Â
© 2016 Hainan Medical University. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Beta-thalassemia; Ferroportin; Hepcidin; Iron overload

Year:  2016        PMID: 27890361     DOI: 10.1016/j.apjtm.2016.07.035

Source DB:  PubMed          Journal:  Asian Pac J Trop Med        ISSN: 1995-7645            Impact factor:   1.226


  9 in total

Review 1.  Pancreatic iron quantification with MR imaging: a practical guide.

Authors:  Antonella Meloni; Vincenzo Positano; Laura Pistoia; Filippo Cademartiri
Journal:  Abdom Radiol (NY)       Date:  2022-05-21

Review 2.  Redox Balance in β-Thalassemia and Sickle Cell Disease: A Love and Hate Relationship.

Authors:  Rayan Bou-Fakhredin; Lucia De Franceschi; Irene Motta; Assaad A Eid; Ali T Taher; Maria Domenica Cappellini
Journal:  Antioxidants (Basel)       Date:  2022-05-13

3.  Assessment of thiol/disulfide balance as an oxidative stress marker in children with β-thalassemia major.

Authors:  Ahmet Guzelcicek; Gokhan Cakirca; Ozcan Erel; Abdullah Solmaz
Journal:  Pak J Med Sci       Date:  2019 Jan-Feb       Impact factor: 1.088

4.  Time to Start Delivering Iron Chelation Therapy in Newly Diagnosed Severe β-Thalassemia.

Authors:  Susi Susanah; Ponpon S Idjradinata; Nur M Sari; Lulu E Rakhmilla; Yunia Sribudiani; Jessica O Trisaputra; Octawyana Moestopo
Journal:  Biomed Res Int       Date:  2020-12-13       Impact factor: 3.411

5.  Iron Status in Newly Diagnosed β-Thalassemia Major: High Rate of Iron Status due to Erythropoiesis Drive.

Authors:  Susi Susanah; Lulu Eva Rakhmilla; Mohammad Ghozali; Jessica Oktavianus Trisaputra; Octawyana Moestopo; Yunia Sribudiani; Ponpon S Idjradinata; Ani Melani Maskoen
Journal:  Biomed Res Int       Date:  2021-04-16       Impact factor: 3.411

6.  Association between iron deposition in splenic,hepatic and myocardial tissues assessed by T2* relaxometry technique.

Authors:  Ali Mohammadzadeh; Saeed Alizadeh; Layla Shojaie; Maryam Mohammadzadeh
Journal:  Caspian J Intern Med       Date:  2021

7.  The Toxic Influence of Excess Free Iron on Red Blood Cells in the Biophysical Experiment: An In Vitro Study.

Authors:  E Kozlova; E Sherstyukova; V Sergunova; A Kozlov; O Gudkova; V Inozemtsev; A Chernysh
Journal:  J Toxicol       Date:  2022-02-26

Review 8.  Activation of STAT and SMAD Signaling Induces Hepcidin Re-Expression as a Therapeutic Target for β-Thalassemia Patients.

Authors:  Hanan Kamel M Saad; Alawiyah Awang Abd Rahman; Azly Sumanty Ab Ghani; Wan Rohani Wan Taib; Imilia Ismail; Muhammad Farid Johan; Abdullah Saleh Al-Wajeeh; Hamid Ali Nagi Al-Jamal
Journal:  Biomedicines       Date:  2022-01-17

Review 9.  Targeting iron metabolism in cancer therapy.

Authors:  Michael Morales; Xiang Xue
Journal:  Theranostics       Date:  2021-07-25       Impact factor: 11.556

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.